A detailed history of Legal & General Group PLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 398,453 shares of TGTX stock, worth $11.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
398,453
Previous 398,453 -0.0%
Holding current value
$11.8 Million
Previous $9.32 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$17.21 - $25.28 $3.95 Million - $5.81 Million
229,735 Added 136.17%
398,453 $9.32 Million
Q2 2024

Aug 14, 2024

BUY
$13.32 - $19.19 $259,233 - $373,475
19,462 Added 13.04%
168,718 $3 Million
Q1 2024

May 14, 2024

BUY
$13.02 - $21.3 $28,097 - $45,965
2,158 Added 1.47%
149,256 $2.27 Million
Q4 2023

Feb 15, 2024

BUY
$6.68 - $18.81 $76,045 - $214,133
11,384 Added 8.39%
147,098 $2.51 Million
Q3 2023

Nov 14, 2023

BUY
$8.36 - $26.5 $19,353 - $61,347
2,315 Added 1.74%
135,714 $1.13 Million
Q2 2023

Aug 14, 2023

BUY
$15.48 - $35.0 $143,375 - $324,170
9,262 Added 7.46%
133,399 $3.31 Million
Q1 2023

May 15, 2023

BUY
$10.23 - $19.34 $103,169 - $195,043
10,085 Added 8.84%
124,137 $1.87 Million
Q4 2022

Feb 14, 2023

SELL
$5.01 - $11.83 $51,623 - $121,896
-10,304 Reduced 8.29%
114,052 $1.35 Million
Q3 2022

Nov 14, 2022

SELL
$4.57 - $8.4 $75,976 - $139,650
-16,625 Reduced 11.79%
124,356 $736,000
Q2 2022

Aug 22, 2022

BUY
$3.74 - $10.66 $117,918 - $336,099
31,529 Added 28.81%
140,981 $599,000
Q1 2022

May 16, 2022

BUY
$7.81 - $20.45 $632 - $1,656
81 Added 0.07%
109,452 $1.04 Million
Q4 2021

Feb 14, 2022

BUY
$15.2 - $35.51 $4,985 - $11,647
328 Added 0.3%
109,371 $2.08 Million
Q3 2021

Nov 15, 2021

BUY
$21.78 - $40.45 $647,715 - $1.2 Million
29,739 Added 37.5%
109,043 $3.63 Million
Q2 2021

Aug 12, 2021

BUY
$32.5 - $48.96 $55,607 - $83,770
1,711 Added 2.21%
79,304 $3.08 Million
Q1 2021

May 17, 2021

BUY
$41.61 - $54.3 $110,058 - $143,623
2,645 Added 3.53%
77,593 $3.74 Million
Q4 2020

Feb 12, 2021

BUY
$25.27 - $54.9 $340,892 - $740,601
13,490 Added 21.95%
74,948 $3.9 Million
Q3 2020

Nov 13, 2020

BUY
$18.49 - $27.24 $702,305 - $1.03 Million
37,983 Added 161.8%
61,458 $1.65 Million
Q2 2020

Aug 14, 2020

BUY
$8.9 - $21.84 $16,020 - $39,312
1,800 Added 8.3%
23,475 $457,000
Q1 2020

May 14, 2020

SELL
$7.14 - $15.99 $26,303 - $58,907
-3,684 Reduced 14.53%
21,675 $213,000
Q4 2019

Feb 13, 2020

BUY
$5.1 - $11.2 $21,435 - $47,073
4,203 Added 19.87%
25,359 $281,000
Q3 2019

Nov 13, 2019

BUY
$5.38 - $8.99 $18,690 - $31,231
3,474 Added 19.65%
21,156 $119,000
Q2 2019

Aug 14, 2019

BUY
$6.27 - $8.65 $47,006 - $64,849
7,497 Added 73.61%
17,682 $153,000
Q3 2018

Nov 20, 2018

BUY
$5.15 - $14.0 $4,604 - $12,516
894 Added 9.62%
10,185 $57,000
Q2 2018

Aug 10, 2018

SELL
$12.5 - $15.0 $3,437 - $4,125
-275 Reduced 2.87%
9,291 $122,000
Q1 2018

May 17, 2018

SELL
$8.7 - $16.8 $34,739 - $67,082
-3,993 Reduced 29.45%
9,566 $136,000
Q4 2017

Feb 13, 2018

BUY
$7.35 - $12.3 $99,658 - $166,775
13,559
13,559 $114,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.